MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study o

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa...

Related Keywords

Massachusetts , United States , Boston , Lugano , Italy General , Italy , Planegg , Bayern , Germany , Canada , German , Italian , American , Julia Neugebauer , Thomas Biegi , Eamonn Nolan , Tim Demuth , Us Oncology Network , Drug Administration , Distribution Services , Nasdaq , German Lymphoma Association , Xencor Inc , Exchange Commission , American Society Of Hematology , Twitter , Constellation Pharmaceuticals Inc , Linkedin , Sys Completes Enrollment , Topline Results Expected , Chief Research , Development Officer , Myelofibrosis Symptom Assessment Form , American Society , Constellation Pharmaceuticals , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Diffuse Largeb Cell Lymphoma , Italian Lymphoma , Blinded Independent Review Committee , Morphosy Annual Report , Corporate News , Regulatory Announcements ,